First tranche delivered, larger tranches en route: the same engine that just produced has visibly more already scheduled
The model's full reasoning — Q1 2017 call → NOWe need to determine if management describes one identifiable engine of new business with both: (1) a first tranche actually landed in the just-reported period, and (2) larger tranches already in motion behind it, with the remainder larger than what has been delivered. The engine must be specific and management must affirm both parts. Let's review the transcript. The call is Q1 2017 earnings. Key products: Vimizim, Kuvan, Naglazyme, Brineura (approved), pegvaliase (filing), vosoritide, BMN 270, BMN 250. We need to find an engine where a first tranche landed in Q1 2017 and larger tranches are already in motion. For example, Brineura was approved last week (after Q1? Actually approval was last week from FDA, and positive CHMP opinion prior week. The call is May 4, 2017. Q1 ended March 31. So Brineura approval is after Q1. So no first tranche landed in Q1 for Brineura. They started U.S. launch, but that's after the quarter. So not in the just-reported period. Vimizim: revenues increased 45% year-over-year, driven by 31% growth in new patients. But that's ongoing business, not a new engine. They added one new market. But is that a first tranche? Probably not. Kuvan: settlement with Par Pharmaceutical for exclusivity to October 2020. That's a legal settlement, not a business engine. Pegvaliase: filing planned later this quarter, not yet approved. No revenue. BMN 270: gene therapy, still in development, no revenue. BMN 250: development. What about the launch of Brineura? It's a new product, but approval came after Q1. So no first tranche in Q1. Maybe the "engine" is the overall commercial portfolio? But that's not specific. Look for something like a new facility, a new contract, a new market expansion. They mentioned "we added one new market for a total of 42 Vimizim markets." That's a new market, but is that a first tranche? Probably not. Another possibility: The settlement with Par Pharmaceutical gives Kuvan exclusivity to October 2020. That's a legal agreement, not a business engine. What about the manufacturing facility for BMN 270? They said "we're well past shovels in the ground for our facility and believe material from this facility will be available to be included in the registration enabling study in the spring of 2018." That's future, not landed. Maybe the "engine" is the expansion of the commercial team for Brineura? No.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| ATAT | Atour Lifestyle Holdings Limited | Q1 2024 | 2024-05-23 | B+ |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| E | Eni S.p.A. | Q1 2024 | 2024-04-24 | B+ |
| FRPH | FRP Holdings, Inc. | Q4 2023 | 2024-03-07 | C+ |
| ZLAB | Zai Lab Limited | Q4 2023 | 2024-02-28 | C |
| VMI | Valmont Industries, Inc. | Q4 2023 | 2024-02-22 | C |
| TBLA | Taboola.com Ltd. | Q3 2023 | 2023-11-08 | B+ |
| JLL | Jones Lang LaSalle Incorporated | Q3 2023 | 2023-11-02 | F |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| CLNE | Clean Energy Fuels Corp. | Q2 2023 | 2023-08-09 | C+ |
| LUCD | Lucid Diagnostics Inc. | Q1 2023 | 2023-05-16 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| ARE | Alexandria Real Estate Equities, Inc. | Q4 2022 | 2023-01-31 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| CDMO | Avid Bioservices, Inc. | Q3 2022 | 2022-03-08 | B+ |
| DG | Dollar General Corporation | Q2 2021 | 2021-08-26 | A |
| DOV | Dover Corporation | Q2 2021 | 2021-07-20 | B+ |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| FEIM | Frequency Electronics, Inc. | Q1 2019 | 2018-09-13 | B+ |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| MGA | Magna International Inc. | Q1 2018 | 2018-05-10 | B+ |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| HR | Healthcare Realty Trust Incorporated | Q1 2017 | 2017-05-08 | A |
| BDN | Brandywine Realty Trust | Q1 2017 | 2017-04-21 | C+ |
| WTS | Watts Water Technologies, Inc. | Q4 2016 | 2017-02-10 | B |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| MTRX | Matrix Service Company | Q3 2016 | 2016-05-05 | D |
| CLF | Cleveland-Cliffs Inc. | Q1 2016 | 2016-04-29 | F |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
CDMO · Q3 2022 → YESThe question is about whether management describes ONE identifiable engine of new business that meets two criteria: NO The transcript describes the first phase of the Myford expansion as now operational and scheduling client projects, with management noting they are already utilizing the new space and that an extra $5 million is arguably in backlog attributable to it.
LINC · Q1 2024 → YESThe question is about whether management describes ONE identifiable engine of new business that meets two criteria: YES The transcript identifies the new-campus expansion strategy as the engine. East Point opened in Q1 with 29 starts and $90k revenue (first tranche, concrete and delivered).
LTRX · Q3 2024 → YESThe question is about whether management describes one identifiable engine of new business that meets two criteria: a first tranche has actually landed in the just-reported period, and larger tranches...